Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

ASCO 2022

Published: 5 Jun 2022

Views: 83

Rating:

Save

Dr Julie Gralow- Chief Medical Officer, ASCO

Dr Julie Gralow comments on a study on chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). rEECur is the first randomised controlled trial in this setting.

The primary outcome was event-free survival (EFS) for the phase III comparison. Secondary outcomes included overall survival (OS), toxicity, and quality of life (QoL).

Dr Gralow concludes the by discussing the significance of the study findings.

Watch Dr McCabe's press conference on the study here

Watch Dr McCabe's interview on the study here

Read the news story here

Related Videos

Treatment management of favourable risk and very favourable risk patients

Dr Guillermo de Velasco and Dr Marco Maruzzo

Treatment management of favourable risk and very favourable risk patients ( Dr Guillermo de Velasco and Dr Marco Maruzzo )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen, Switzerland

CAR-T therapy and impact to cancer patient outcomes and experience of treatment ( Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen, Switzerland )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer